Mercado M, Abreu C, Vergara-López A, et al. - In the present study, the researchers sought to analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Data from the MAR informatic platform have been extracted. In total, 650 surgical outcomes were analyzed (94.6% transsphenoidal). According to results, surgical remission, defined by a postoperative postglucose (GH) of less than 1 ng/mL and an insulin-like growth factor 1 (IGF-1) of less than 1.2 × upper limit of normal (ULN), was achieved in 40.15%, while 44.15% remained biochemically active. Persistently active disease after surgery was significantly linked to harboring an invasive macroadenoma, a basal GH of greater than 10 ng/mL, and/or an IGF-1 of greater than 2 × ULN at diagnosis on bivariate and multivariate analysis. Findings suggested that surgical and pharmacological outcomes in acromegaly are highly dependent on tumor size/invasiveness and on the degree of hypersomatotropinemia.